Naohiro Makise
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naohiro Makise has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Akinobu Araki
Division of Surgical Pathology Chiba Cancer Center Chiba Japan
10 shared publicationsMariko Oikawa
Division of Surgical Pathology Chiba Cancer Center Chiba Japan
10 shared publicationsTakahiro Sugiyama
Division of Surgical Pathology Chiba Cancer Center Chiba Japan
9 shared publicationsTsukasa Yonemoto
Division of Orthopaedic Surgery Chiba Cancer Center Chiba Japan
9 shared publicationsYoko Hagiwara
Department of Orthopedic Surgery Chiba Cancer Center Chiba Japan
9 shared publicationsHajime Kageyama
Division of Surgical Pathology Chiba Cancer Center Chiba Japan
8 shared publications
Latest Publications
- 17 September 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (9) , e70174
Nano‐ RAPID : Integrated Diagnosis for Sarcoma Using a Nanopore Sequencer
Pathological diagnosis of sarcoma is challenging. Although high‐throughput sequencing and methylation array aid sarcoma diagnosis and are routine in high‐income countries, access to these genetic/epigenetic analyses in many countries, including Japan, remains limited. Nanopore sequencing is an easy, fast, and cost‐effective high‐throughput sequencing alternative. Nanopore sequencers read long‐read DNA to detect fusion DNA and 5‐methyl‐cytosine in single nucleotide resolution, enabling real‐time basecalling for selective enrichment of regions of interest via “adaptive sampling.” Nanopore sequencing of Raw DNA with Adaptive sampling for Prompt Integrated Diagnosis (Nano‐RAPID) was developed to test its diagnostic utility. This study included 22 retrospective and nine prospective cases. DNA extracted from fresh/frozen tissue was sequenced for 46–98 h, followed by approximately 12 h of data analysis. Consequently, disease‐specific/characteristic fusion genes were detected in 10 retrospective and six prospective cases. Disease‐specific single nucleotide variants were detected in three cases, while disease‐specific amplifications were detected in two retrospective cases. Monosomy, trisomy, and chromosomal instability were also detected. Methylation analyses accurately classified 15 retrospective and five prospective cases. Collectively, correct tumor types were identified using at least one modality in 19 retrospective and nine prospective cases. Halving the consumables and re‐analyzing 24‐h data yielded nearly equivalent results, suggesting faster and cost‐effective analyses. In conclusion, Nano‐RAPID may be a promising adjunctive for sarcoma diagnosis. Nano‐RAPID could be introduced in low‐equipped hospitals to assist non‐specialized pathologists diagnosing sarcoma. Since this study remains exploratory, further studies with larger cohort should be needed.
- 17 September 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (9) , e70174
Nano‐ RAPID : Integrated Diagnosis for Sarcoma Using a Nanopore Sequencer
Pathological diagnosis of sarcoma is challenging. Although high‐throughput sequencing and methylation array aid sarcoma diagnosis and are routine in high‐income countries, access to these genetic/epigenetic analyses in many countries, including Japan, remains limited. Nanopore sequencing is an easy, fast, and cost‐effective high‐throughput sequencing alternative. Nanopore sequencers read long‐read DNA to detect fusion DNA and 5‐methyl‐cytosine in single nucleotide resolution, enabling real‐time basecalling for selective enrichment of regions of interest via “adaptive sampling.” Nanopore sequencing of Raw DNA with Adaptive sampling for Prompt Integrated Diagnosis (Nano‐RAPID) was developed to test its diagnostic utility. This study included 22 retrospective and nine prospective cases. DNA extracted from fresh/frozen tissue was sequenced for 46–98 h, followed by approximately 12 h of data analysis. Consequently, disease‐specific/characteristic fusion genes were detected in 10 retrospective and six prospective cases. Disease‐specific single nucleotide variants were detected in three cases, while disease‐specific amplifications were detected in two retrospective cases. Monosomy, trisomy, and chromosomal instability were also detected. Methylation analyses accurately classified 15 retrospective and five prospective cases. Collectively, correct tumor types were identified using at least one modality in 19 retrospective and nine prospective cases. Halving the consumables and re‐analyzing 24‐h data yielded nearly equivalent results, suggesting faster and cost‐effective analyses. In conclusion, Nano‐RAPID may be a promising adjunctive for sarcoma diagnosis. Nano‐RAPID could be introduced in low‐equipped hospitals to assist non‐specialized pathologists diagnosing sarcoma. Since this study remains exploratory, further studies with larger cohort should be needed.
- 29 August 2026
- Published by Springer Nature in Head and Neck Pathology
- Vol. 20 (1) , 94
Inflammatory Rhabdomyoblastic Tumor with Malignant Progression of the Neck: Unique Copy Number Profile Identified by Nanopore Sequencing
Inflammatory rhabdomyoblastic tumors (IRMT) are newly described entities characterized by a near-haploid karyotype. Most IRMTs exhibit indolent behavior; however, rare malignant transformation has been reported. We report a case of IRMT with malignant progression. Case Presentation A 67-year-old man presented with a painless mass in the left neck. Radiology revealed a 40-mm tumor in the left sternocleidomastoid muscle, with no evidence of distant metastasis. Results Core needle biopsy showed densely proliferating polygonal cells with pleomorphic nuclei, necrosis, and atypical mitoses. Based on histology, a preliminary diagnosis of pleomorphic rhabdomyosarcomas was made, although the clinical behavior seemed atypical. Nanopore DNA sequencing was subsequently performed and, within days, revealed characteristic molecular features, including relative gains of chromosomes 5, 7, and 22, a TP53 mutation, and DNA methylation profiling consistent with IRMT with malignant progression. The tumor was surgically resected, and pathological examination of the resected specimen confirmed a minor conventional IRMT component. Furthermore, infiltration of CD163-positive histiocytes was prominent, and fluorescence in situ hybridization analysis revealed two red signals (COL1A1 on chromosome 17) and four green signals (PDGFB on chromosome 22) in most tumor cells. Collectively, these histopathological, immunohistochemical, cytogenetic, and epigenetic findings established a final diagnosis of IRMT with malignant progression. Conclusions Given the small tumor size, chemotherapy and radiotherapy were not administered. Nevertheless, the long-term behavior of IRMT with malignant progression remains unclear; thus, careful follow-up is warranted.
- 29 August 2026
- Published by Springer Nature in Head and Neck Pathology
- Vol. 20 (1) , 94
Inflammatory Rhabdomyoblastic Tumor with Malignant Progression of the Neck: Unique Copy Number Profile Identified by Nanopore Sequencing
Inflammatory rhabdomyoblastic tumors (IRMT) are newly described entities characterized by a near-haploid karyotype. Most IRMTs exhibit indolent behavior; however, rare malignant transformation has been reported. We report a case of IRMT with malignant progression. Case Presentation A 67-year-old man presented with a painless mass in the left neck. Radiology revealed a 40-mm tumor in the left sternocleidomastoid muscle, with no evidence of distant metastasis. Results Core needle biopsy showed densely proliferating polygonal cells with pleomorphic nuclei, necrosis, and atypical mitoses. Based on histology, a preliminary diagnosis of pleomorphic rhabdomyosarcomas was made, although the clinical behavior seemed atypical. Nanopore DNA sequencing was subsequently performed and, within days, revealed characteristic molecular features, including relative gains of chromosomes 5, 7, and 22, a TP53 mutation, and DNA methylation profiling consistent with IRMT with malignant progression. The tumor was surgically resected, and pathological examination of the resected specimen confirmed a minor conventional IRMT component. Furthermore, infiltration of CD163-positive histiocytes was prominent, and fluorescence in situ hybridization analysis revealed two red signals (COL1A1 on chromosome 17) and four green signals (PDGFB on chromosome 22) in most tumor cells. Collectively, these histopathological, immunohistochemical, cytogenetic, and epigenetic findings established a final diagnosis of IRMT with malignant progression. Conclusions Given the small tumor size, chemotherapy and radiotherapy were not administered. Nevertheless, the long-term behavior of IRMT with malignant progression remains unclear; thus, careful follow-up is warranted.
- 24 July 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (7)
Intramuscular Myoepithelioma‐Like Hyalinizing Epithelioid Tumor With OGT::FOXO3 Intraexonic DNA Fusion Confirmed by Nanopore Sequencing
Myoepithelioma‐like hyalinizing epithelioid tumor (MHET) is a rare mesenchymal neoplasm characterized by rearrangements of the OGT gene. MHET typically presents as a small tumor in the subcutis and generally follows a benign clinical course. Histologically, MHET is characterized by a hyalinized stroma exhibiting a distinctive “two‐tone” appearance, epithelioid tumor cells with cellular processes encircling matrix globules, and a minor spindle cell component. The tumor also demonstrates rich vasculature with occasional fringe‐like vessels, accompanied by perivascular concentric spindle cell proliferation and hyalinization. Nearly all documented OGT fusions in MHET are intraexonic; however, their precise genomic DNA breakpoints and the mechanisms underlying fusion transcript generation remain unclear. We report a case of MHET in a 17‐year‐old boy and investigate the genomic breakpoint of the fusion gene. Although the tumor showed atypical features, including large size, intramuscular location, and focal cytokeratin (CAM5.2) expression, the histologic findings were characteristic of MHET. Reverse transcription‐polymerase chain reaction (RT‐PCR) identified an intraexonic, in‐frame OGT::FOXO3 fusion transcript. To clarify the genomic breakpoint, nanopore DNA sequencing demonstrated that the DNA breakpoint was identical to the fusion junction in the mRNA transcript. These findings demonstrate that the fusion transcript was generated directly from rearranged genomic DNA without splice site involvement. This mechanism may contribute to the rarity of MHET and warrants further investigation.
- 24 July 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (7)
Intramuscular Myoepithelioma‐Like Hyalinizing Epithelioid Tumor With OGT::FOXO3 Intraexonic DNA Fusion Confirmed by Nanopore Sequencing
Myoepithelioma‐like hyalinizing epithelioid tumor (MHET) is a rare mesenchymal neoplasm characterized by rearrangements of the OGT gene. MHET typically presents as a small tumor in the subcutis and generally follows a benign clinical course. Histologically, MHET is characterized by a hyalinized stroma exhibiting a distinctive “two‐tone” appearance, epithelioid tumor cells with cellular processes encircling matrix globules, and a minor spindle cell component. The tumor also demonstrates rich vasculature with occasional fringe‐like vessels, accompanied by perivascular concentric spindle cell proliferation and hyalinization. Nearly all documented OGT fusions in MHET are intraexonic; however, their precise genomic DNA breakpoints and the mechanisms underlying fusion transcript generation remain unclear. We report a case of MHET in a 17‐year‐old boy and investigate the genomic breakpoint of the fusion gene. Although the tumor showed atypical features, including large size, intramuscular location, and focal cytokeratin (CAM5.2) expression, the histologic findings were characteristic of MHET. Reverse transcription‐polymerase chain reaction (RT‐PCR) identified an intraexonic, in‐frame OGT::FOXO3 fusion transcript. To clarify the genomic breakpoint, nanopore DNA sequencing demonstrated that the DNA breakpoint was identical to the fusion junction in the mRNA transcript. These findings demonstrate that the fusion transcript was generated directly from rearranged genomic DNA without splice site involvement. This mechanism may contribute to the rarity of MHET and warrants further investigation.
- 10 March 2026
- Published by Wiley in Histopathology
- Vol. 89 (1) , 110-121
HMGA2 expression in CIC ‐rearranged sarcoma and other small round/epithelioid cell tumours
Aims: CIC ‐rearranged sarcoma (CRS), a highly aggressive sarcoma, is characterized by CIC fusion, with DUX4 being the most common partner. CRS is among the most difficult tumours to diagnose. Besides its relatively nonspecific small round or epithelioid morphology, genetic analyses often fail to detect CIC rearrangements. Although several diagnostic markers for CRS, namely WT1, MUC5AC, ETV4 and DUX4, have been introduced, their accessibility and interpretability are limited. Prompted by previous RNA‐seq studies, we investigated the diagnostic utility of HMGA2 immunohistochemistry. Methods: HMGA2 immunohistochemistry was evaluated in institutional archival cases from 2000 to 2025. Nine CRS and 119 other small round/epithelioid cell tumours were included. GATA3 and FOSL1 were also tested in selected CRS cases. Results: HMGA2 was frequently positive for CRS, with a sensitivity of 78% (strong expression) or 100% (any expression). It was positive in other small round epithelioid cell tumours, including a subset of Ewing sarcoma, EWSR1::NFATC2 sarcoma, sclerosing epithelioid fibrosarcoma, mesenchymal tumours with ACTB::GLI1 fusion, and malignant melanoma. Overall, the specificity was 82% (strong expression) and 70% (any expression). HMGA2 was more readily interpretable than WT1 and MUC5AC, and double‐negative CRS cases were strongly positive for HMGA2. Three cases were negative for GATA3 and FOSL1. Conclusions: HMGA2 may be more readily implemented than ETV4 and DUX4, even in non‐specialized hospitals. Thus, HMGA2 immunohistochemistry is a useful adjunct for CRS diagnosis. HMGA2 expression in CRS and other small round or epithelioid cell tumours should be tested in a larger series, particularly in non‐ DUX4 CRS and ATXN1/ATXN1L ‐rearranged sarcomas.
- 10 March 2026
- Published by Wiley in Histopathology
- Vol. 89 (1) , 110-121
HMGA2 expression in CIC ‐rearranged sarcoma and other small round/epithelioid cell tumours
Aims: CIC ‐rearranged sarcoma (CRS), a highly aggressive sarcoma, is characterized by CIC fusion, with DUX4 being the most common partner. CRS is among the most difficult tumours to diagnose. Besides its relatively nonspecific small round or epithelioid morphology, genetic analyses often fail to detect CIC rearrangements. Although several diagnostic markers for CRS, namely WT1, MUC5AC, ETV4 and DUX4, have been introduced, their accessibility and interpretability are limited. Prompted by previous RNA‐seq studies, we investigated the diagnostic utility of HMGA2 immunohistochemistry. Methods: HMGA2 immunohistochemistry was evaluated in institutional archival cases from 2000 to 2025. Nine CRS and 119 other small round/epithelioid cell tumours were included. GATA3 and FOSL1 were also tested in selected CRS cases. Results: HMGA2 was frequently positive for CRS, with a sensitivity of 78% (strong expression) or 100% (any expression). It was positive in other small round epithelioid cell tumours, including a subset of Ewing sarcoma, EWSR1::NFATC2 sarcoma, sclerosing epithelioid fibrosarcoma, mesenchymal tumours with ACTB::GLI1 fusion, and malignant melanoma. Overall, the specificity was 82% (strong expression) and 70% (any expression). HMGA2 was more readily interpretable than WT1 and MUC5AC, and double‐negative CRS cases were strongly positive for HMGA2. Three cases were negative for GATA3 and FOSL1. Conclusions: HMGA2 may be more readily implemented than ETV4 and DUX4, even in non‐specialized hospitals. Thus, HMGA2 immunohistochemistry is a useful adjunct for CRS diagnosis. HMGA2 expression in CRS and other small round or epithelioid cell tumours should be tested in a larger series, particularly in non‐ DUX4 CRS and ATXN1/ATXN1L ‐rearranged sarcomas.
- 26 January 2026
- Published by Springer Nature in Virchows Archiv
Selective MYC 5′ amplification in postirradiation/lymphedema-associated angiosarcoma
We assessed whether an endothelium-specific enhancer is co-amplified with MYC in postirradiation/lymphedema-associated angiosarcoma (PLAS). First, the signal pattern and diagnostic utility of MYC break-apart fluorescence in situ hybridization (FISH) were examined to distinguish PLAS from carcinoma. Next, public data were analyzed to determine the association between the MYC-co-amplified region and cell type-specific active enhancers. Six cases of PLAS were retrieved, including three with a history of breast cancer. Additionally, we retrieved 23 MYC-amplified carcinoma cases, of which seven were breast cancers. MYC break-apart FISH was performed in all cases. The MYC-co-amplified regions in angiosarcoma and other carcinomas were explored using cBioportal. Endothelium-specific active enhancers were searched using H3K4me1 and H3K27ac chromatin immunoprecipitation-sequencing data on ENCODE. MYC break-apart FISH analysis revealed selective 5' amplification in all six PLAS cases, whereas 16 of 23 carcinomas, as well as six of seven MYC-amplified breast cancers, exhibited dual-signal amplification. cBioportal data analysis revealed 5' skewing of the MYC-co-amplified region in angiosarcoma, which was not readily apparent in other carcinomas. ENCODE chromatin immunoprecipitation-sequencing data analysis revealed endothelium-specific active enhancers upstream of MYC; the cell/tissue-type-specific 3' enhancer was not conspicuous. In conclusion, MYC break-apart FISH is a useful adjunctive tool for distinguishing PLAS from carcinoma. The 5' skewing of the MYC-co-amplified region, possibly associated with an endothelium-specific active enhancer, was confirmed. Subsequent studies involving larger case series, higher-resolution genomic experiments, and single-cell epigenetic experiments are required.
- 26 January 2026
- Published by Springer Nature in Virchows Archiv
Selective MYC 5′ amplification in postirradiation/lymphedema-associated angiosarcoma
We assessed whether an endothelium-specific enhancer is co-amplified with MYC in postirradiation/lymphedema-associated angiosarcoma (PLAS). First, the signal pattern and diagnostic utility of MYC break-apart fluorescence in situ hybridization (FISH) were examined to distinguish PLAS from carcinoma. Next, public data were analyzed to determine the association between the MYC-co-amplified region and cell type-specific active enhancers. Six cases of PLAS were retrieved, including three with a history of breast cancer. Additionally, we retrieved 23 MYC-amplified carcinoma cases, of which seven were breast cancers. MYC break-apart FISH was performed in all cases. The MYC-co-amplified regions in angiosarcoma and other carcinomas were explored using cBioportal. Endothelium-specific active enhancers were searched using H3K4me1 and H3K27ac chromatin immunoprecipitation-sequencing data on ENCODE. MYC break-apart FISH analysis revealed selective 5' amplification in all six PLAS cases, whereas 16 of 23 carcinomas, as well as six of seven MYC-amplified breast cancers, exhibited dual-signal amplification. cBioportal data analysis revealed 5' skewing of the MYC-co-amplified region in angiosarcoma, which was not readily apparent in other carcinomas. ENCODE chromatin immunoprecipitation-sequencing data analysis revealed endothelium-specific active enhancers upstream of MYC; the cell/tissue-type-specific 3' enhancer was not conspicuous. In conclusion, MYC break-apart FISH is a useful adjunctive tool for distinguishing PLAS from carcinoma. The 5' skewing of the MYC-co-amplified region, possibly associated with an endothelium-specific active enhancer, was confirmed. Subsequent studies involving larger case series, higher-resolution genomic experiments, and single-cell epigenetic experiments are required.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Radiology
- Vol. 2026 (1) , 2643786
Prostate Cancer Recurrence Mimicking a Primary Paranasal Sinus Tumor on 18 F‐FDG PET/CT During Treatment for Metastases After 10 Years of Remission
Metastatic tumors of the nasal cavity and paranasal sinuses are rare, and the prostate is a particularly uncommon primary site. Including metastatic prostate cancer in the differential diagnosis of sinonasal tumors can be clinically challenging. To our knowledge, there are no detailed case reports confirming uptake in paranasal sinus metastases from prostate cancer using 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT). The patient was a 68‐year‐old man who was diagnosed with prostate cancer 16 years prior to his visit. After a 10‐year remission, he received radiation therapy and radium‐223 for prostate cancer 6 years earlier, followed by multiple courses of radiation therapy for lymph node and bone metastases over the next 5 years. His chief complaints were a 2‐month history of nasal congestion and a postnasal drip. The tumor was located mainly in the right paranasal sinus and showed signs of bone infiltration and tumor necrosis. FDG‐PET/CT showed intense uptake in the mass (maximum standardized uptake value = 15.2). The differential diagnosis included primary and metastatic tumors. Biopsy revealed histological features similar to the primary prostate cancer site from 16 years prior, with prostatic acid phosphatase and NKX3.1 positive staining. The patient was diagnosed with metastatic prostate cancer, underwent palliative radiotherapy, and passed away approximately 23 months after the detection of paranasal sinus metastasis. This case highlights the importance of considering metastasis even in atypical lesions in patients with prostate cancer.
- 1 January 2026
- Published by Wiley in Case Reports in Radiology
- Vol. 2026 (1) , 2643786
Open AccessProstate Cancer Recurrence Mimicking a Primary Paranasal Sinus Tumor on 18 F‐FDG PET/CT During Treatment for Metastases After 10 Years of Remission
Metastatic tumors of the nasal cavity and paranasal sinuses are rare, and the prostate is a particularly uncommon primary site. Including metastatic prostate cancer in the differential diagnosis of sinonasal tumors can be clinically challenging. To our knowledge, there are no detailed case reports confirming uptake in paranasal sinus metastases from prostate cancer using 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT). The patient was a 68‐year‐old man who was diagnosed with prostate cancer 16 years prior to his visit. After a 10‐year remission, he received radiation therapy and radium‐223 for prostate cancer 6 years earlier, followed by multiple courses of radiation therapy for lymph node and bone metastases over the next 5 years. His chief complaints were a 2‐month history of nasal congestion and a postnasal drip. The tumor was located mainly in the right paranasal sinus and showed signs of bone infiltration and tumor necrosis. FDG‐PET/CT showed intense uptake in the mass (maximum standardized uptake value = 15.2). The differential diagnosis included primary and metastatic tumors. Biopsy revealed histological features similar to the primary prostate cancer site from 16 years prior, with prostatic acid phosphatase and NKX3.1 positive staining. The patient was diagnosed with metastatic prostate cancer, underwent palliative radiotherapy, and passed away approximately 23 months after the detection of paranasal sinus metastasis. This case highlights the importance of considering metastasis even in atypical lesions in patients with prostate cancer.
- 7 November 2024
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (11)
Sporadic Breast Angiosarcoma With MYC Amplification on Extrachromosomal Circular DNA Detected Using Nanopore Sequencing in an Adolescent Female
Angiosarcoma (AS) is a malignant vascular neoplasm comprising neoplastic endothelial cells accounting for 1%–4% of soft tissue sarcomas. While lymphedema‐associated and post‐irradiation ASs are almost always driven by a high‐level amplification of MYC (8q24), sporadic ASs, including those of breast parenchymal origin, typically lack MYC amplification. Here, we report a case of sporadic breast MYC‐amplified AS in a 19‐year‐old female with no history of lymphedema or irradiation, who was referred to our hospital for an enlarging right breast mass. After needle biopsy, the patient underwent right mastectomy and axillary lymphadenectomy. Microscopically, atypical endothelial cells proliferated and formed well‐defined or slit‐like vascular channels that invaded and dissected the breast parenchymal fat, ducts, and lobules. In a limited area, the tumor cells showed solid sheet‐like proliferation with increased mitotic figures of 40 per 2 mm2 with a small area of necrosis. Immunohistochemical analysis revealed strong positivity for c‐Myc. Fluorescence in situ hybridization (FISH) with MYC break‐apart probes showed a high‐level 5′ single signal amplification. The patient was disease‐free 16 months post‐surgery. Nanopore sequencing successfully detected not only a high‐level amplification of the 8q24 region, including MYC, but also multiple structural variants of the 8q24 region. In‐depth analysis revealed extrachromosomal circular DNA amplification including the MYC protein‐coding region and upstream region but not the downstream region. We also performed methylation classification using nanopore‐based methylation data to successfully categorize the tumor as AS. This case report highlights the potential utility of nanopore sequencing in the diagnosis of sarcomas.
- 7 November 2024
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (11)
Sporadic Breast Angiosarcoma With MYC Amplification on Extrachromosomal Circular DNA Detected Using Nanopore Sequencing in an Adolescent Female
Angiosarcoma (AS) is a malignant vascular neoplasm comprising neoplastic endothelial cells accounting for 1%–4% of soft tissue sarcomas. While lymphedema‐associated and post‐irradiation ASs are almost always driven by a high‐level amplification of MYC (8q24), sporadic ASs, including those of breast parenchymal origin, typically lack MYC amplification. Here, we report a case of sporadic breast MYC‐amplified AS in a 19‐year‐old female with no history of lymphedema or irradiation, who was referred to our hospital for an enlarging right breast mass. After needle biopsy, the patient underwent right mastectomy and axillary lymphadenectomy. Microscopically, atypical endothelial cells proliferated and formed well‐defined or slit‐like vascular channels that invaded and dissected the breast parenchymal fat, ducts, and lobules. In a limited area, the tumor cells showed solid sheet‐like proliferation with increased mitotic figures of 40 per 2 mm2 with a small area of necrosis. Immunohistochemical analysis revealed strong positivity for c‐Myc. Fluorescence in situ hybridization (FISH) with MYC break‐apart probes showed a high‐level 5′ single signal amplification. The patient was disease‐free 16 months post‐surgery. Nanopore sequencing successfully detected not only a high‐level amplification of the 8q24 region, including MYC, but also multiple structural variants of the 8q24 region. In‐depth analysis revealed extrachromosomal circular DNA amplification including the MYC protein‐coding region and upstream region but not the downstream region. We also performed methylation classification using nanopore‐based methylation data to successfully categorize the tumor as AS. This case report highlights the potential utility of nanopore sequencing in the diagnosis of sarcomas.
- 29 July 2024
- Published by Wiley in Pathology International
- Vol. 74 (10) , 604-610
Fluorescence in situ hybridization‐negative intra‐articular myxoid liposarcoma with complex rearrangements involving EWSR1::DDIT3 detected using nanopore sequencing
Myxoid liposarcoma (MLPS) is a rare sarcoma, typically arising in deep soft tissues during the fourth to fifth decades of life. Histologically, MLPS is composed of uniform oval cells within a background of myxoid stroma and chicken‐wire capillaries. Genetically, MLPS is characterized by the FUS/EWSR1::DDIT3 fusion gene, which generally results from balanced interchromosomal translocation and is detectable via DDIT3 break‐apart fluorescence in situ hybridization (FISH). Here, we report an unusual intra‐articular MLPS case, negative for DDIT3 break‐apart FISH but positive for EWSR1::DDIT3. An 18‐year‐old female was referred to our hospital complaining of an intra‐articular mass in the right knee joint. Histologically, the tumor was mainly composed of mature adipocytes, brown fat‐like cells, and lipoblasts. Nanopore sequencing detected DNA rearrangements between EWSR1 and DDIT3 and clustered complex rearrangements involving multiple chromosomes, suggesting chromoplexy. Methylation classification using random forest, t‐distributed stochastic neighbor embedding, and unsupervised hierarchical clustering correctly classified the tumor as MLPS. The copy number was almost flat. The TERT promoter C‐124T was also detected. This report highlights, for the first time, the potential value of a fast and low‐cost nanopore sequencer for diagnosing sarcomas.
- 29 July 2024
- Published by Wiley in Pathology International
- Vol. 74 (10) , 604-610
Fluorescence in situ hybridization‐negative intra‐articular myxoid liposarcoma with complex rearrangements involving EWSR1::DDIT3 detected using nanopore sequencing
Myxoid liposarcoma (MLPS) is a rare sarcoma, typically arising in deep soft tissues during the fourth to fifth decades of life. Histologically, MLPS is composed of uniform oval cells within a background of myxoid stroma and chicken‐wire capillaries. Genetically, MLPS is characterized by the FUS/EWSR1::DDIT3 fusion gene, which generally results from balanced interchromosomal translocation and is detectable via DDIT3 break‐apart fluorescence in situ hybridization (FISH). Here, we report an unusual intra‐articular MLPS case, negative for DDIT3 break‐apart FISH but positive for EWSR1::DDIT3. An 18‐year‐old female was referred to our hospital complaining of an intra‐articular mass in the right knee joint. Histologically, the tumor was mainly composed of mature adipocytes, brown fat‐like cells, and lipoblasts. Nanopore sequencing detected DNA rearrangements between EWSR1 and DDIT3 and clustered complex rearrangements involving multiple chromosomes, suggesting chromoplexy. Methylation classification using random forest, t‐distributed stochastic neighbor embedding, and unsupervised hierarchical clustering correctly classified the tumor as MLPS. The copy number was almost flat. The TERT promoter C‐124T was also detected. This report highlights, for the first time, the potential value of a fast and low‐cost nanopore sequencer for diagnosing sarcomas.
- 9 July 2024
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (7) , e23254
Nanopore DNA Sequencing Detected Chromothripsis‐Induced PAFAH1B1::USP6 Rearrangement in Periosteal Solid Aneurysmal Bone Cyst Initially Diagnosed as Osteosarcoma
An aneurysmal bone cyst (ABC) is a benign bone neoplasm that typically occurs during the first and second decades of life. ABC usually presents as a rapidly growing intramedullary expansile mass with multiple blood‐filled cysts in the metaphysis of the long tubular bones. Here, we report a case of a periosteal solid ABC that was initially diagnosed as a high‐grade surface osteosarcoma. A 10‐year‐old male was referred to our hospital for swelling and tenderness of the left upper arm. Radiography revealed periosteal mass without fluid–fluid levels. On performing open biopsy, the tumor showed hypercellular proliferation of uniform spindle to epithelioid cells with brisk mitotic activity (up to 12/2 mm2) and lace‐like osteoid formation, which was diagnosed as a high‐grade surface osteosarcoma. After one course of chemotherapy using adriamycin and cisplatin, peripheral sclerosis was conspicuous, which led to pathological review and revision of diagnosis as “possibly osteoblastoma.” The patient was disease‐free for 4 years after marginal resection and curettage. Retrospective nanopore DNA sequencing unexpectedly detected a PAFAH1B1::USP6 rearrangement. The fusion gene was further validated using reverse transcription‐polymerase chain reaction and the diagnosis was revised to ABC. Chromothripsis involving chromosome 17 has also been identified. Methylation analysis classified the present tumor as an ABC or non‐ossifying fibroma using t‐distributed stochastic neighbor embedding and unsupervised hierarchical clustering. This case report highlights the utility of nanopore DNA sequencing for soft tissue and bone tumor diagnosis.
- 9 July 2024
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (7) , e23254
Nanopore DNA Sequencing Detected Chromothripsis‐Induced PAFAH1B1::USP6 Rearrangement in Periosteal Solid Aneurysmal Bone Cyst Initially Diagnosed as Osteosarcoma
An aneurysmal bone cyst (ABC) is a benign bone neoplasm that typically occurs during the first and second decades of life. ABC usually presents as a rapidly growing intramedullary expansile mass with multiple blood‐filled cysts in the metaphysis of the long tubular bones. Here, we report a case of a periosteal solid ABC that was initially diagnosed as a high‐grade surface osteosarcoma. A 10‐year‐old male was referred to our hospital for swelling and tenderness of the left upper arm. Radiography revealed periosteal mass without fluid–fluid levels. On performing open biopsy, the tumor showed hypercellular proliferation of uniform spindle to epithelioid cells with brisk mitotic activity (up to 12/2 mm2) and lace‐like osteoid formation, which was diagnosed as a high‐grade surface osteosarcoma. After one course of chemotherapy using adriamycin and cisplatin, peripheral sclerosis was conspicuous, which led to pathological review and revision of diagnosis as “possibly osteoblastoma.” The patient was disease‐free for 4 years after marginal resection and curettage. Retrospective nanopore DNA sequencing unexpectedly detected a PAFAH1B1::USP6 rearrangement. The fusion gene was further validated using reverse transcription‐polymerase chain reaction and the diagnosis was revised to ABC. Chromothripsis involving chromosome 17 has also been identified. Methylation analysis classified the present tumor as an ABC or non‐ossifying fibroma using t‐distributed stochastic neighbor embedding and unsupervised hierarchical clustering. This case report highlights the utility of nanopore DNA sequencing for soft tissue and bone tumor diagnosis.
- 15 May 2024
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (5) , e23246
Metastasizing aneurysmal dermatofibroma initially diagnosed as angiosarcoma confirmed by CD63::PRKCD fusion gene detection with nanopore sequencing
Dermatofibroma (DF) is a benign tumor that forms pedunculated lesions ranging in size from a few millimeters to 2 cm, usually affecting the extremities and trunks of young adults. Histopathologically, DF is characterized by the storiform proliferation of monomorphic fibroblast‐like spindle cells. In addition to neoplastic cells, secondary elements such as foamy histiocytes, Touton‐type giant cells, lymphoplasmacytes, and epidermal hyperplasia are characteristic histological features. Several histological variants, including atypical, cellular, aneurysmal, and lipidized variants, have been reported; cases with variant histologies are sometimes misdiagnosed as sarcomas. We present a case of metastasizing aneurysmal DF that was initially diagnosed as an angiosarcoma on biopsy. A 26‐year‐old woman was referred to our hospital with a gradually enlarging subcutaneous mass in her lower left leg. Positron emission tomography‐computed tomography revealed high fluorodeoxyglucose uptake not only in the tumor but also in the left inguinal region. On biopsy, ERG and CD31‐positive atypical spindle cells proliferated in slit‐like spaces with extravasation, leading to the diagnosis of angiosarcoma. Histology of the wide‐resection specimen was consistent with DF, and lymph node metastasis was also observed. Nanopore DNA sequencing detected CD63::PRKCD fusion and copy number gain, although CD63 was not included in the target region of adaptive sampling. This report highlights the importance of recognizing the unusual clinical, radiological, and pathological features of DF to avoid misdiagnosis, and the potential diagnostic utility of nanopore sequencer.
- 15 May 2024
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (5) , e23246
Metastasizing aneurysmal dermatofibroma initially diagnosed as angiosarcoma confirmed by CD63::PRKCD fusion gene detection with nanopore sequencing
Dermatofibroma (DF) is a benign tumor that forms pedunculated lesions ranging in size from a few millimeters to 2 cm, usually affecting the extremities and trunks of young adults. Histopathologically, DF is characterized by the storiform proliferation of monomorphic fibroblast‐like spindle cells. In addition to neoplastic cells, secondary elements such as foamy histiocytes, Touton‐type giant cells, lymphoplasmacytes, and epidermal hyperplasia are characteristic histological features. Several histological variants, including atypical, cellular, aneurysmal, and lipidized variants, have been reported; cases with variant histologies are sometimes misdiagnosed as sarcomas. We present a case of metastasizing aneurysmal DF that was initially diagnosed as an angiosarcoma on biopsy. A 26‐year‐old woman was referred to our hospital with a gradually enlarging subcutaneous mass in her lower left leg. Positron emission tomography‐computed tomography revealed high fluorodeoxyglucose uptake not only in the tumor but also in the left inguinal region. On biopsy, ERG and CD31‐positive atypical spindle cells proliferated in slit‐like spaces with extravasation, leading to the diagnosis of angiosarcoma. Histology of the wide‐resection specimen was consistent with DF, and lymph node metastasis was also observed. Nanopore DNA sequencing detected CD63::PRKCD fusion and copy number gain, although CD63 was not included in the target region of adaptive sampling. This report highlights the importance of recognizing the unusual clinical, radiological, and pathological features of DF to avoid misdiagnosis, and the potential diagnostic utility of nanopore sequencer.